drugset / Trial / NCT03775395
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2018-12-12
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |